Duane Boise CEO stated, “As cannabinoid policy shifts from retail access toward physician directed treatment and insurance participation, companies with IND programs, orphan-drug positioning, and botanical drug pipelines-like MMJ International Holdings-are emerging as the sector’s most strategically aligned opportunities”.
WASHINGTON, April 6, 2026 (Newswire.com)
–
As cannabis stocks rally following new federal flexibility on hemp derived CBD products, investors are asking a deeper question: which companies are actually positioned to succeed under the emerging FDA led cannabinoid regulatory framework?
Cannabis equities surged this week after the U.S. Food and Drug Administration announced it would exercise enforcement discretion toward certain physician-directed hemp-derived oral CBD products participating in the new Medicare cannabinoid access initiative.
The announcement helped propel the AdvisorShares Pure U.S. Cannabis ETF up 16% for the week, its strongest performance since December, while major operators posted meaningful gains they are unprepared for FDA drug development.
But while markets reacted quickly to the headline, experienced healthcare investors are focusing on a more important development:
The federal government is signaling that cannabinoid access will expand – but under a medical framework increasingly shaped by the FDA.
That distinction matters.
And it explains why MMJ International Holdings may represent one of the most strategically positioned companies in the cannabinoid sector today.
FDA Enforcement Discretion Changes the Investment Landscape
The policy allows Medicare beneficiaries access to physician-directed CBD supplements within defined safety and labeling boundaries.
This is not legalization.
It is not full regulatory approval.
But it is a signal that the federal government is preparing structured medical access pathways for cannabinoids.
Markets noticed immediately.
Yet most public cannabis companies benefiting from the rally remain primarily:
retail-focused
state-regulated
supplement-adjacent
or internationally fragmented operators
MMJ International Holdings is different.
The Sector Is Rallying – But the Regulatory Winners Will Be Pharmaceutical
Many investors still misunderstand the difference between:
single-molecule botanical-derived drugs
and
FDA botanical drugs
Approximately 20-25% of approved pharmaceuticals originate from plant-derived molecules.
Those drugs can be synthesized once identified.
But botanical drugs are far more complex.
They contain:
multi-compound plant extracts
variable terpene interactions
minor cannabinoid contributions
matrix-dependent pharmacokinetics
Standardizing them requires advanced chemistry, manufacturing, and controls (CMC).
That complexity explains why the FDA has approved only four botanical drugs in modern regulatory history.
MMJ International Holdings is developing one of them.
MMJ Is Already Operating Inside the FDA Drug Development System
While most cannabis companies are reacting to policy shifts, MMJ has spent years preparing for them.
Its cannabinoid therapeutics platform includes:
FDA IND clinical program infrastructure
Orphan Drug Designation for Huntington’s disease
standardized botanical soft-gel dosage formulation
DEA Schedule I analytical laboratory authorization
pharmaceutical-grade extract characterization
controlled clinical supply architecture
This is the pathway institutional healthcare capital follows.
Not dispensary expansion.
Medicare CBD Coverage Strengthens MMJ’s Strategic Position
The CMS pilot allowing reimbursement for hemp-derived cannabinoid products represents a structural shift in federal policy.
It confirms three important signals:
the federal government accepts cannabinoid therapeutic potential
physician-directed cannabinoid access is expanding
insurance linked cannabinoid pathways are emerging
But the program also creates a policy contradiction:
supplement-grade cannabinoids can now receive reimbursement
while clinical-trial cannabinoid manufacturing remains constrained
That gap increases the relative importance of companies already positioned inside the FDA approval framework.
MMJ is one of them.
Why Traditional Cannabis Operators Face Structural Limits
Companies like Tilray, Canopy Growth, and Curaleaf benefited from this week’s rally.
However, they remain constrained by:
exchange listing barriers
interstate commerce restrictions
state-level regulatory fragmentation
absence of FDA clinical drug pipelines
The FDA’s botanical drug pathway represents an entirely different category of value creation.
It produces:
reimbursable medicines
insurance coverage eligibility
exclusive indications
orphan-drug protection
pharmaceutical partnerships
That is where long-term capital moves.
The Rare Opportunity Created by Botanical Drug Development
Developing an FDA-approved botanical cannabinoid drug is difficult.
That is precisely why it is valuable.
Few companies attempt it.
Fewer succeed.
MMJ International Holdings has already completed major components of the hardest regulatory work:
1.standardization
2.dose reproducibility
3.extract characterization
4.clinical-trial preparation
The company is not reacting to federal policy changes.
It anticipated them.
Statement From CEO Duane Boise
“The FDA’s decision to allow physician-directed cannabinoid access through Medicare confirms what we have said for years,” said Duane Boise, CEO of MMJ International Holdings. “Cannabinoids belong inside the medical system. Companies that followed the FDA clinical pathway are positioned to lead the next phase of this industry.”
The Market Is Beginning to Recognize the Difference
This week’s cannabis stock rally reflects excitement.
But regulatory structure determines outcomes.
As cannabinoids move closer to physician-directed access, reimbursement eligibility, and FDA-aligned oversight, companies operating inside the pharmaceutical pathway stand to benefit the most.
MMJ International Holdings is already there.
CONTACT:
Madison Hisey
MHisey@mmjih.com
203-231-85832
SOURCE: MMJ International Holdings
Source: MMJ International Holdings
